hospitalizations

COAPT™ Trial Results Demonstrate Long-Term Benefits of Abbott’s MitraClip™ Device

Source Node: https://zephyrnet.com/late-breaking-data-from-landmark-coapt-trial-show-long-term-benefits-of-abbotts-mitraclip-device/
Time Stamp: March 4, 2023 7:00 PM - Modified On: March 4, 2023 - Published By:
Source Cluster:
Published by Plato

for Heart Failure Patients Recent findings from the COAPT™ clinical trial have demonstrated the long-term benefits of Abbott's MitraClip™ device for heart failure patients. The trial, which was conducted by the Cardiovascular Research Foundation, showed that the MitraClip™ device significantly reduced hospitalizations and improved quality of life for patients with heart failure. The MitraClip™ device is a minimally invasive device that is used to treat mitral regurgitation, a condition in which the mitral valve does not close properly and allows blood to flow backward in the heart. The device works

Abbott’s TriClip™ Device Demonstrates Superiority to Medical Therapy for Treating Tricuspid Regurgitation in New Data

Source Node: https://zephyrnet.com/new-data-show-superiority-of-abbotts-triclip-device-compared-to-medical-therapy-for-tricuspid-regurgitation/
Time Stamp: March 3, 2023 7:00 PM - Modified On: March 3, 2023 - Published By:
Source Cluster:
Published by Plato

Treating tricuspid regurgitation (TR) is a challenge for cardiologists, as the condition can lead to serious complications and even death. Abbott’s TriClip™ device has emerged as a promising solution to this problem. In a new study, researchers have demonstrated the superiority of the TriClip™ device over medical therapy for treating TR.TR is a condition where the tricuspid valve, which separates the right atrium and right ventricle of the heart, does not close properly. This causes blood to flow backward from the right ventricle into the right atrium, leading to an